LISATA THERAPEUTICS, INC. (LSTA) Stock Profile — Insider Trades & Financials

EPS$-1.91

Market Cap$45.2M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

David Mazzo

CEO & Executive Director

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Founded: 1980
Employees: 21
Headquarters: Basking Ridge, New Jersey, United States

⚡

Core Efficiency

D/E Ratio?

0.21

📊

Profitability Ratios

Current Ratio?

5.76

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 23, 2026 (in 136 days)

Annual Report (10-K) — Based on filing pattern

Aug 23, 2026

Predicted10-K

Mar 12, 2026

10-KQ4 20240d after period end

Mar 12, 2026

10-KFY 202471d after period end

Nov 6, 2025

10-QQ3 20250d after period end

Aug 7, 2025

10-QQ2 20250d after period end

May 8, 2025

10-QQ1 20250d after period end

Feb 27, 2025

10-KFY 202458d after period end

Nov 12, 2024

10-QQ3 20240d after period end

Aug 12, 2024

10-QQ2 20240d after period end

Loading company sections...

LISATA THERAPEUTICS, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness